Dencker S J
Neuropsychiatry Unit, Institute of Clinical Neurosciences, Sahlgrenska University Hospital, Goteborg, Sweden.
Acta Psychiatr Scand Suppl. 2000;402:6-11. doi: 10.1034/j.1600-0447.2000.02602.x.
The selective serotonin reuptake inhibitors (SSRIs) have obtained global attention but have not demonstrated superior efficacy in major depression compared with older tricyclic antidepressants. From a pharmacological viewpoint the noradrenergic system in the brain appears to have a central role in neurotransmitter organization. The importance of noradrenaline in depression is supported by its association with clinical parameters such as vigilance and drive. Reboxetine is a selective noradrenaline reuptake inhibitor--the first in its class to be marketed. In both preclinical and clinical studies reboxetine has been found to be an effective and safe antidepressant. Furthermore, reboxetine restores a patients' social functioning, producing a better quality of remission than fluoxetine.
选择性5-羟色胺再摄取抑制剂（SSRIs）已引起全球关注，但与较老的三环类抗抑郁药相比，在重度抑郁症中未显示出更优的疗效。从药理学角度来看，大脑中的去甲肾上腺素能系统似乎在神经递质组织中起核心作用。去甲肾上腺素与警觉性和驱力等临床参数相关，这支持了其在抑郁症中的重要性。瑞波西汀是一种选择性去甲肾上腺素再摄取抑制剂，是该类药物中首个上市的药物。在临床前和临床研究中，瑞波西汀均被发现是一种有效且安全的抗抑郁药。此外，瑞波西汀可恢复患者的社交功能，产生比氟西汀更好的缓解质量。
